FOR RESEARCH USE ONLY
Clinical trial literatureMetabolic research

Cagrilintide

Long-acting amylin analogue researched for appetite suppression, satiety and adjunctive weight-management protocols.

01Amylin receptors02Satiation03Gastric emptying
Molecular signature / cagrilintide
Structural identity

Acylated amylin analogue designed for sustained receptor activity

Also known as

AM833 · Long-acting amylin analogue

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

Cagrilintide is a long-acting analogue of human amylin, a pancreatic peptide co-secreted with insulin that regulates satiety, gastric emptying and post-prandial glucose excursions. It is studied both as a standalone investigational agent and in combination with GLP-1 receptor agonists for amplified weight-loss and glycaemic outcomes.

The research question

Cagrilintide targets amylin receptors involved in satiation, gastric emptying and post-meal glucagon regulation. Combination research with incretin compounds is particularly important because overlapping gastrointestinal effects can shape tolerability.

Section 02

Mechanism & research themes

Activates amylin receptors in the area postrema and other hindbrain nuclei to suppress appetite and reduce food intake. Also slows gastric emptying and modulates post-meal glucagon secretion, complementing the incretin effects of GLP-1-based therapies.

01

Potent appetite suppression via central amylin-receptor activation

02

Slowed gastric emptying and improved post-prandial glycaemic control

03

Synergistic weight-loss potential when combined with GLP-1 agonists

04

Reduced food cravings and improved portion control in research models

05

May preserve lean mass better than calorie restriction alone

06

Investigational cardiometabolic benefits beyond weight loss

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Clinical trial literature

Human trials include standalone and combination research, but long-term evidence is less mature than that for established GLP-1 treatments. Dose frequency must be taken from the specific study formulation.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Clinical studies use once-weekly subcutaneous administration with gradual dose escalation. Published escalation schedules begin at 0.3mg weekly and increase at specified intervals according to the study design and tolerability; studied maintenance doses extend to 4.5mg weekly. Trial durations commonly range from 20 to 68 weeks.

Reported persistence

Approximately 159–195 hours (about 7–8 days), supporting once-weekly administration in clinical studies.

Calculator starting point

0.3 mg per reference dose

1 doses per week · 20-week cycle

2 mL default reconstitution volume

Clinical studies use once-weekly SC dosing with stepwise escalation from 0.3 mg according to the study schedule and tolerability.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate Cagrilintide
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 10mg vial with 2–3mL bacteriostatic water for a 3.3–5mg/mL working concentration. Swirl gently — do not shake.

Storage reference

Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 28 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Nausea, vomiting and constipation are common class effects, particularly during dose escalation.

L2

Hypoglycaemia risk increases when combined with insulin or sulfonylureas.

L3

Human safety data beyond Phase 2 remains limited; pancreatitis and gallbladder disease precautions mirror GLP-1 class.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only